Arrowstreet Capital
NBIX icon

Arrowstreet Capital’s Neurocrine Biosciences NBIX Stock Holding History

Arrowstreet Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-360,711
Closed -$51.2M – 2017
2025
Q4 		$51.2M Sell
360,711
-50,949
-12% -$7.38M 0.03% 475
2025
Q3 		$57.8M Buy
411,660
+286,498
+229% +$38.8M 0.04% 417
2025
Q2 		$15.7M Buy
125,162
+58,562
+88% +$6.72M 0.01% 765
2025
Q1 		$7.37M Buy
+66,600
New +$8.44M 0.01% 892
2024
Q4 		– Sell
-8,651
Closed -$997K – 1892
2024
Q3 		$997K Buy
8,651
+5,169
+148% +$709K ﹤0.01% 1388
2024
Q2 		$479K Sell
3,482
-27,281
-89% -$3.74M ﹤0.01% 1339
2024
Q1 		$4.24M Buy
+30,763
New +$4.2M ﹤0.01% 938
2023
Q3 		– Sell
-71,770
Closed -$6.77M – 1361
2023
Q2 		$6.77M Sell
71,770
-4,842
-6% -$473K 0.01% 578
2023
Q1 		$7.75M Buy
76,612
+12,386
+19% +$1.29M 0.01% 594
2022
Q4 		$7.67M Sell
64,226
-143,124
-69% -$16.8M 0.01% 583
2022
Q3 		$22M Buy
207,350
+100,361
+94% +$10.2M 0.03% 357
2022
Q2 		$10.4M Buy
106,989
+10,706
+11% +$988K 0.01% 488
2022
Q1 		$9.03M Sell
96,283
-16,099
-14% -$1.36M 0.01% 532
2021
Q4 		$9.57M Buy
+112,382
New +$10.3M 0.01% 664
2020
Q4 		– Sell
-12,900
Closed -$1.24M – 2452
2020
Q3 		$1.24M Buy
+12,900
New +$1.49M ﹤0.01% 1753
2018
Q4 		– Sell
-18,400
Closed -$2.26M – 1448
2018
Q3 		$2.26M Buy
+18,400
New +$2.09M 0.01% 664
2018
Q2 		– Sell
-18,600
Closed -$1.54M – 1233
2018
Q1 		$1.54M Buy
+18,600
New +$1.57M ﹤0.01% 789
2014
Q1 		– Sell
-60,409
Closed -$564K – 1263
2013
Q4 		$564K Sell
60,409
-42,881
-42% -$418K ﹤0.01% 948
2013
Q3 		$1.17M Buy
+103,290
New +$1.42M 0.01% 633

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's NBIX Position: Q1 2026 in Review

Arrowstreet Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 360,711 shares — an estimated $51.2M sold.

Arrowstreet Capital first reported a position in NBIX in Q3 2013 and held it in 19 quarters. The position peaked at $57.8M in Q3 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Arrowstreet Capital reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 360,711 Neurocrine Biosciences shares in Q1 2026, an estimated $51.2M.
  • Arrowstreet Capital first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 19 quarters.
  • Arrowstreet Capital's Neurocrine Biosciences position peaked at $57.8M in Q3 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.